Innovative Approaches in the Treatment and Management of Heart Failure: Managed Care Considerations on the Role of New and Emerging Therapies

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2023 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2023 to August 1, 2024

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Merck Sharp & Dohme LLC

Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. Projections show that by 2030, the prevalence of heart failure will increase 46 percent from recent estimates. HF is the reason for more than 1 million hospitalizations per year and an estimated $31 billion in costs in the U.S. each year. While recent efforts have focused on improving the outlook for patients with chronic heart failure, mortality and morbidity following admission for heart failure remain significant. Fortunately for patients with HF, new and emerging therapeutic options have entered the treatment paradigm in recent years, including selective cardiac myosin activators, showing the ability to improve clinical and economic outcomes for the patient and system, which makes it imperative to update medical directors, practicing physicians, nurses and other healthcare professionals on recent clinical data and recommendation updates regarding these new therapy options.

Upon completion of this activity, participants will be able to:

  • Review the challenges, clinical burden, associated comorbidities, and the emerging role of biomarkers in heart failure (HF)

  • Examine the incidence and prevalence of HF, the difference between heart failure with preserved or reduced ejection fraction (HFpEF or HFrEF), diagnostic testing, and prognosis

  • Compare and contrast new and emerging therapies, including sGC stimulators and SGLT2 inhibitors, for HF based on mechanism of action, safety, and efficacy, including options for patients with high-risk HF with HRrEF

  • Identify patients at high risk for worsening heart failure to prevent life-threatening events through prompt intervention

  • Assess clinical practices with current evidence and guideline-directed medical therapy (GDMT) for treatment initiation, monitoring, and optimization

  • Examine the cost drivers associated with the management of heart failure and the value of evolving novel treatment approaches in lowering cost of care and healthcare utilization


Faculty: Akshay Desai, MD, MPH
Medical Director, Cardiomyopathy and Heart Failure Program, Advanced Heart Disease Section
Brigham and Women's Hospital
Associate Professor
Harvard Medical School


(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Desai has served as a consultant for Abbott, Alnylam, AstraZeneca, Avidity Biopharma, Axon Therapeutics, Bayer, Biofourmis, Cytokinetics, GlaxoSmithKline, Merck, Novartis, Medpace, Parexel, Regeneron, River2Renal, Veristat, Verily, and Zydus. He has received grant/research support from Abbott, Alnylam, AstraZeneca, Bayer, Pfizer, and Novartis. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Merck Sharp & Dohme LLC

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue